The Developmental Biology and Solid Tumor Program (DBSTP) brings together 30 members, including 26 Full and four Associate (junior mentored) Members from nine departments with the shared goal of improving outcomes for children and adolescents with solid tumors. In 2009, the Program underwent a change in leadership, prompted by the departure from the SJCCC of Dr. Peter Houghton (then co-leader of the Program). At that time, the SJCCC took the opportunity to reinvigorate the Program, undertaking a collaborative restructuring process that resulted in a translational research pipeline that integrates basic, translational and clinical research. The Program is now structured around three highly-integrated focus groups: (i) The Basic Research Group: This group employs developmental biology and genomic approaches to better understand the processes regulating normal development and how these processes are deregulated in childhood solid tumors. This group also includes an innovative drug discovery and drug development effort to advance molecular-targeted therapies relevant to pediatric solid tumors (ii) Translational Research Group: The translational research group provides an essential bridge between the basic and clinical research groups and is focused on the development and implementation of innovative new methods for testing therapeutics in preclinical models to guide clinical trial development. Investigators in the translational research group have expertise in pharmacokinetics and pharmacodynamics, animal models of pediatric solid tumors, and statistical design of preclinical and clinical trials, (iii) The Clinical Research Group: conducts cutting-edge clinical trials for patients with solid tumors and participates in national collaborative clinical trials through the Children's Oncology Group (COG) and other consortia. The DBSTP is supported by $6.0 million in cancer-focused grants ($4.7 million peer-reviewed, $1.3 million non-peer reviewed), and research in the program has led to 465 publications during the funding period of which 22% (n=102/465) represent intraprogrammatic collaborations, and 29% (n= 136/465) represent interprogrammatic collaborations.
Solid tumors account for 30% of all childhood cancer deaths. Despite improvements in therapy, progress in age-adjusted mortality trends have become stagnant over the past 20 years. Outcomes for children with recurrent or metastatic solid malignancies are particularly poor. The DBSTP, together with the unique resources and collaborations available across the Cancer Center, is working to develop new therapies for these childhood cancers and reduce late effects for survivors.
|Fernandez-Pineda, I; Ortega-Laureano, L; Wu, H et al. (2016) Guidewire Catheter Exchange in Pediatric Oncology: Indications, Postoperative Complications, and Outcomes. Pediatr Blood Cancer 63:1081-5|
|Zhou, Sheng; Fatima, Soghra; Ma, Zhijun et al. (2016) Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes. Mol Ther 24:1090-9|
|Walsh, Kyle M; Whitehead, Todd P; de Smith, Adam J et al. (2016) Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. Carcinogenesis 37:576-82|
|Verbist, Katherine C; Guy, Cliff S; Milasta, Sandra et al. (2016) Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 532:389-93|
|Edginton, Andrea N; Zimmerman, Eric I; Vasilyeva, Aksana et al. (2016) Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemother Pharmacol 77:1039-52|
|Paugh, Steven W; Bonten, Erik J; Evans, William E (2016) Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Mol Cell Oncol 3:e1065947|
|Yeh, Jennifer M; Hanmer, Janel; Ward, Zachary J et al. (2016) Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst 108:|
|Zhao, Yunqian; Nguyen, Phuong; Ma, Jing et al. (2016) Preferential Use of Public TCR during Autoimmune Encephalomyelitis. J Immunol 196:4905-14|
|Interiano, Rodrigo B; Malkan, Alpin D; Loh, Amos H P et al. (2016) Initial diagnostic management of pediatric bone tumors. J Pediatr Surg 51:981-5|
|Snaman, Jennifer M; Kaye, Erica C; Torres, Carlos et al. (2016) Parental Grief Following the Death of a Child from Cancer: The Ongoing Odyssey. Pediatr Blood Cancer 63:1594-602|
Showing the most recent 10 out of 6391 publications